ScholarLens Back to search
2010•Zhongguo yiyuan ganranxue zazhiRequires access

Clinical Analysis of Piperacillin/tazobactam for Acute Stroke-associated Pneumonia

Cneh JiZhi, Sun Jianfa, Bing Li, Zaichun Deng

Open publisher page 0 citations

Abstract

OBJECTIVE To evaluate the clinical efficacy of Piperacillin/tazobactam for acute stroke-associated pneumonia.METHODS 83 cases of acute stroke-associated pneumonia patients who were microbiologically diagnosed were randomized into Piperacillin/tazobactam group and Ceftazidime group,and sputum culture was undertaken twice after treatment.RESULTS The total efficacy rates and bacterial clean rates in Piperacillin/tazobactam group and Ceftazidime group were 90.48%,92.86% and 70.73%,75.61% respectively,and the differences between the two groups were statistically significant.CONCLUSIONS It suggests that Piperacillin/tazobactam is a more effective drug for acute stroke-associated pneumonia.

About this research paper

What this paper is about

OBJECTIVE To evaluate the clinical efficacy of Piperacillin/tazobactam for acute stroke-associated pneumonia.METHODS 83 cases of acute stroke-associated pneumonia patients who were microbiologically diagnosed were randomized into Piperacillin/tazobactam group and Ceftazidime group,and sputum culture was undertaken twice after treatment.RESULTS The total efficacy rates and bacterial clean rates in Piperacillin/tazobactam group and Ceftazidime group were 90.48%,92.86% and 70.73%,75.61% respectively,and the differences between the two groups were statistically significant.CONCLUSIONS It suggests that Piperacillin/tazobactam is a more effective drug for acute stroke-associated pneumonia.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE To evaluate the clinical efficacy of Piperacillin/tazobactam for acute stroke-associated pneumonia.METHODS 83 cases of acute stroke-associated pneumonia patients who were microbiologically diagnosed were randomized into Piperacillin/tazobactam group and Ceftazidime group,and sputum culture was undertaken twice after treatment.RESULTS The total efficacy rates and bacterial clean rates in Piperacillin/tazobactam group and Ceftazidime group were 90.48%,92.86% and 70.73%,75.61% respectively,and the differences between the two groups were statistically significant.CONCLUSIONS It suggests that Piperacillin/tazobactam is a more effective drug for acute stroke-associated pneumonia.

Key concepts: Piperacillin/tazobactam, Medicine, Piperacillin, Tazobactam, Ceftazidime, Pneumonia, Internal medicine, Hospital-acquired pneumonia

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical Analysis of Piperacillin/tazobactam for Acute Stroke-associated Pneumonia — Research Paper | ScholarLens